Table 2.

HR values of meta-analysis overall, by cancer site and individual studies.

Study	n	HR	Lower CI	Upper CI	p-value	I2 Heterogeneity
ALL SOLID TUMORS	5337	0.34	0.26	0.46	<0.0001	86.9%
Head and Neck Cancer	667	0.31	0.11	0.85	0.030	94.7%
Hsia et al. 2005	38	0.61	0.21	1.82	0.378
Lu et al. 2017	197	0.46	0.27	0.77	0.004
Svensson et al. 2017	97	0.49	0.28	0.86	0.012
Taghavi et al. 2016	57	0.06	0.01	0.26	0.001
Wagner et al. 2016	140	0.32	0.10	0.96	0.042
Xu et al. 2016	138	0.60	0.39	0.91	0.016
Breast Cancer	1481	0.27	0.09	0.68	0.027	85%
Muntasell et al. 2018	71	0.07	0.01	0.60	0.01
Muntasell et al. 2018	41	0.30	0.08	1.30	0.10
Rathore et al. 2014	175	1.92	1.08	3.57	0.05
Tian et al. 2016	278	0.54	0.39	0.74	0.001
Triki et al. 2019	158	0.17	0.04	0.73	0.017
Wang et al. 2014 (ALDH1high)	379	1.10	0.50	2.44	0.811
Wang et al. 2014 (ALDH1low)	379	0.12	0.01	0.81	0.031
Colorectal Cancer	1663	0.38	0.22	0.68	0.019	0%
Alderdice et al. 2018	150	0.28	0.11	0.73	0.005
Menon et al. 2014	93	0.43	0.17	1.01	0.030
Sconocchia et al. 2011	1420	0.43	0.30	0.70	0.0020
Gastric Cancer	115	0.52	0.01	47.35	0.32	0%
Pernot et al. 2020	40	0.40	0.15	1.06	0.040
Svensson et al. 2017	75	0.84	0.41	1.70	0.619
Lung Cancer	94	0.47	0.05	4.11	0.14	0%
Villegas et al. 2002	50	0.43	0.20	0.95	0.036
Yamada et al. 2010	44	0.66	0.25	1.78	0.41
Liver Cancer	377	0.29	0.03	2.67	0.14	91.8%
Chew et al. 2012	40	0.12	0.04	0.31	0.0010
Wu et al. 2013	256	0.63	0.40	0.99	0.046
Zhu et al. 2009	81	0.38	0.17	0.85	0.019
Ovarian Cancer	365	0.57	0.26	1.24	0.089	0%
Henriksen et al. 2019	283	0.67	0.46	0.98	0.031
Li et al. 2009 (intra-epithelial)	41	0.38	0.15	0.99	0. 048
Li et al. 2009 (stromal)	41	1.62	0.15	5.32	0.27
Endometrial Cancer
Versluis et al. 2017	355	0.85	0.56	1.29	0.445
Periampullary Cancer
Lundgren et al. 2016 (Intestinal)	87.5	0.23	0.07	0.78	0.05
Lundgren et al. 2016 (PA)	87.5	0.59	0.34	1.02	Not reported
Gallbladder Cancer
Nakakubo et al. 2003	45	0.56	0.20	1.58	0.2655